Qrons Inc. announced that it formed a collaboration with scientists at one of the largest public research universities in Israel, by which Tellurium based compounds in combination with Qrons' QS200™ product candidate and other configurations will be experimented as treatment for diffused axonal injuries (also commonly referred to as concussions) which accounts for approximately 89% of Traumatic Brain Injuries ("TBIs"). Furthermore, preliminary studies conducted over the last several months under the collaboration suggests that some configurations may have significant therapeutic effect on antibiotic resistant bacteria infections and Sepsis. Dependent on funding, Qrons plans on proceeding to the next phase which shall include a pre-clinical and a limited pilot clinical experimental program to verify the preliminary findings and expand its IP portfolio.

According to the CDC Sepsis is the body's extreme response to an infection. It is a life-medical emergency. Without timely effective treatment, sepsis can rapidly lead to tissue damage, organ failure, and death.

The CDC further reports that each year in the U.S. more than 1.7 million people develop sepsis, and at least 350,000 adults who develop sepsis die during their hospitalization or are discharged to hospice. 1 in 3 people who dies in a hospital had sepsis during that hospitalization.